Valuation : Entrada Therapeutics, Inc.

Market Cap 257M 221M 208M 190M 355M 24.31B 356M 2.47B 953M 12.45B 965M 944M 39.66B P/E 2026 *
-1.79x
P/E 2027 * -1.99x
Enterprise Value 227M 195M 184M 168M 313M 21.46B 314M 2.18B 841M 10.99B 852M 834M 35.01B EV / Sales 2026 *
16.3x
EV / Sales 2027 * -0.96x
Free-Float
85.77%
Yield 2026 *
-
Yield 2027 * -
1 day-0.56%
1 week+1.86%
Current month+1.13%
1 month+3.78%
3 months+11.93%
6 months-43.32%
Current year-30.64%
1 week 6.8
Extreme 6.8
7.42
1 month 6.76
Extreme 6.76
7.79
Current year 5.63
Extreme 5.63
16.45
1 year 5.02
Extreme 5.02
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 01/08/2017
Director of Finance/CFO 47 01/11/2020
President 56 01/01/2024
Director TitleAgeSince
Director/Board Member 50 01/08/2017
Chairman 45 01/12/2020
Director/Board Member 67 01/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26
MPM BioImpact LLC
SellCompany -32,263 0.0829%
3/9/26
MPM BioImpact LLC
SellCompany -32,263 0.0829%
2/9/26 Tax

Chief Executive Officer

-8,724 0.0224%
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%+1.86%+34.78%-48.63% 257M
-0.38%-2.64%+42.69%+99.03% 67.98B
-2.71%-0.71%+34.08%+81.43% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-1.42%-4.28%+31.24%+13.27% 25.74B
-1.11%+0.90%+23.12%-18.50% 20.09B
+1.15%-14.24%+219.82%+381.14% 17.16B
+0.20%-4.68%-6.41%+560.92% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average -0.45%+1.13%+41.44%+159.85% 27.94B
Weighted average by Cap. -0.81%+0.59%+36.96%+140.94%

Financials

2026 *2027 *
Net sales 13.89M 11.95M 11.24M 10.26M 19.19M 1.31B 19.25M 133M 51.5M 673M 52.18M 51.03M 2.14B 22.86M 19.66M 18.49M 16.88M 31.57M 2.16B 31.67M 219M 84.74M 1.11B 85.85M 83.97M 3.53B
Net income -173M -149M -140M -128M -239M -16.39B -240M -1.66B -643M -8.4B -651M -637M -26.74B -182M -157M -148M -135M -252M -17.25B -253M -1.75B -676M -8.83B -685M -670M -28.13B
Net Debt -30.12M -25.91M -24.37M -22.24M -41.6M -2.85B -41.73M -289M -112M -1.46B -113M -111M -4.65B -279M -240M -226M -206M -385M -26.39B -387M -2.68B -1.03B -13.52B -1.05B -1.03B -43.05B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
04/09/26 USD 7.130 -0.56% 341,729
03/09/26 USD 7.170 -1.78% 395,559
02/09/26 USD 7.300 +3.25% 306,542
01/09/26 USD 7.070 +0.28% 205,483
31/08/26 USD 7.050 +0.71% 450,412
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.130USD
Average target price
19.00USD
Spread / Average Target
+166.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!